Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Advanced Non-Small Cell Lung Cancer (ATLANTIC)
NCT02087423Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate at 12 months. Started Feb 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02087423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02087423.